rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    COLL
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?
      Nov 17Yahoo FinanceCOLL
      Wall Street Analysts Believe Collegium Pharmaceutical (COLL) Could Rally 81.63%: Here's is How to Trade
      Nov 10Yahoo FinanceCOLL
      Collegium Pharmaceutical (COLL) Stock Gets Fair Value Trim As Analysts Weigh Pain And ADHD
      Nov 10Yahoo FinanceCOLL
      Collegium Pharmaceutical Inc (COLL) (Q3 2026) Earnings Call Highlights: ADHD Franchise Hits ...
      Nov 6Yahoo FinanceCOLL
      Jefferies cuts Collegium Pharmaceutical stock price target on pain business concerns
      Nov 6Investing.comCOLL
      Collegium Pharmaceutical, Inc. Q3 2026 Earnings Call Summary
      Nov 5Yahoo FinanceCOLL
      Collegium Pharmaceutical Q3 Earnings Call Highlights
      Nov 5Yahoo FinanceCOLL
      Collegium Pharmaceutical Q3 2026 Earnings Call Transcript
      Nov 5BenzingaCOLL
      Collegium Pharmaceutical earnings beat by $0.10, revenue fell short of estimates
      Nov 5Investing.comCOLL
      Collegium Pharmaceutical (COLL) Tops Q3 Earnings and Revenue Estimates
      Nov 5Yahoo FinanceCOLL
      Collegium Pharmaceutical (NASDAQ:COLL) posts in line Q3 2026 sales and full year revenue guidance above estimates, stock soars
      Nov 5Yahoo FinanceCOLL
      Compared to Estimates, Collegium Pharmaceutical (COLL) Q3 Earnings: A Look at Key Metrics
      Nov 5Yahoo FinanceCOLL
      Collegium Pharmaceutical: Q3 Earnings Snapshot
      Nov 5Yahoo FinanceCOLL
      Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance
      Nov 5Yahoo FinanceCOLL
      Collegium Pharmaceutical (COLL) Repositioning: Shifting Focus from Pain Management to ADHD
      Nov 2Yahoo FinanceCOLL
      Earnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to Decline
      Oct 29Yahoo FinanceCOLL
      Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts
      Oct 29Yahoo FinanceCOLL
      Q2 earnings highs and lows: Collegium Pharmaceutical (NASDAQ:COLL) vs the rest of the branded pharmaceuticals stocks
      Oct 26Yahoo FinanceCOLL
      Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026
      Oct 22Yahoo FinanceCOLL
      Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses
      Oct 21Yahoo FinanceCOLL
      Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance Cut (NASDAQ:COLL)
      Oct 17Seeking AlphaCOLL
      Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?
      Oct 16Yahoo FinanceCOLL
      Collegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer Says
      Oct 9Yahoo FinanceCOLLOPY
      Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life
      Oct 6Yahoo FinanceCOLL
      Collegium Pharmaceutical Reports Q2 2026 Results: Full Earnings Call Transcript - Collegium Pharmaceutica

      Collegium Pharmaceutical (NASDAQ:COLL) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive

      Oct 5BenzingaCOLL
      Oppenheimer initiates Collegium Pharmaceutical stock at Outperform
      Sep 23Investing.comCOLL
      Oppenheimer Initiates Collegium Pharmaceutical at Outperform With $50 Price Target
      Sep 23Yahoo FinanceCOLL
      Collegium's Durable Cash Flow From Pain Portfolio Poised to Support Further Business Development, Oppenheimer Says
      Sep 23Yahoo FinanceCOLL
      Collegium Pharmaceutical at H.C. Wainwright: pushing beyond pain
      Sep 16Investing.comCOLL
      Leerink Partners Initiates Coverage on Collegium Pharmaceutical With Outperform Rating, $45 Price Target
      Sep 9Yahoo FinanceCOLL
      Truist Cuts Price Target on Collegium Pharmaceutical to $49 From $58, Keeps Buy Rating
      Sep 9Yahoo FinanceCOLL
      Collegium to Participate in Upcoming Investor Conferences

      STOUGHTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that its management will participate in the following investor conferences: Morgan Stanley 24th Annual Global Healthcare ConferenceFireside Chat Date and Time: Tuesday, September 15, 2026, at 4:05 p.m. ETNew York, NY H.C. Wainwright 28th Annual Global

      Sep 8Yahoo FinanceCOLL

      This is the newest page. Registered accounts read further back.